Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Average Rating of “Hold” from Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have earned a consensus rating of “Hold” from the fifteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $486.6667.

MEDP has been the topic of several research analyst reports. Truist Financial lowered their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target for the company in a research note on Tuesday, February 10th. Barclays raised shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price objective for the company in a report on Friday, March 6th. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Mizuho set a $582.00 target price on shares of Medpace in a report on Wednesday, February 11th.

Hedge Funds Weigh In On Medpace

A number of institutional investors and hedge funds have recently modified their holdings of MEDP. Fifth Third Wealth Advisors LLC increased its position in Medpace by 2.6% during the third quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after acquiring an additional 19 shares during the last quarter. BOKF NA boosted its position in Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after purchasing an additional 20 shares during the last quarter. Valeo Financial Advisors LLC boosted its position in Medpace by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after purchasing an additional 21 shares during the last quarter. HighPoint Advisor Group LLC grew its stake in shares of Medpace by 2.8% during the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares during the period. Finally, UMB Bank n.a. grew its stake in shares of Medpace by 5.6% during the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after purchasing an additional 24 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Trading Down 7.1%

Shares of MEDP opened at $443.85 on Friday. The company has a market cap of $12.60 billion, a price-to-earnings ratio of 29.01, a P/E/G ratio of 2.29 and a beta of 1.44. The business’s fifty day simple moving average is $526.03 and its two-hundred day simple moving average is $538.58. Medpace has a 12 month low of $250.05 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company’s revenue was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts forecast that Medpace will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.